Vascepa icosapent ethyl: Completed Phase III enrollment

Amarin completed enrollment of >8,000 patients with elevated triglyceride levels and either coronary heart disease (CHD)

Read the full 168 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE